TITLE

What doesn't kill you

AUTHOR(S)
Martindale, Diane
PUB. DATE
October 2003
SOURCE
New Scientist;10/25/2003, Vol. 180 Issue 2418, p38
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Dishing out drugs that make your symptoms worse seems like a rash, even dangerous way to treat patients. Miracle workers rarely come back for an encore, but in the world of heart medicine one little miracle is bucking the trend. Beta blockers were invented in 1964 and quickly became the most widely used drugs for controlling high blood pressure, saving countless lives. And now they're doing it all over again, this time for congestive heart failure.
ACCESSION #
11279162

 

Related Articles

  • Expanding Indications for Beta-Blockers in Heart Failure. Braunwald, Eugene // New England Journal of Medicine;05/31/2001, Vol. 344 Issue 22, p1711 

    Editorial. Discusses the use of beta-blockers to treat heart failure. Two studies in this issue which report on the effects of beta-blockade and which appear to have come to opposite conclusions; Prudence of remaining alert to racial differences in the response to beta-blockers in future...

  • Left Ventricular Dysfunction: Carvedilol vs. Metoprolol. Sadovsky, Richard // American Family Physician;2/15/2004, Vol. 69 Issue 4, p958 

    Provides information on carvedilol, a non-selective beta blocker. Effects of the carvedilol therapy to patients with congestive heart failure and left ventricular dysfunction; Recommended dosages; Adverse effects and contraindications.

  • A nurse-facilator intervention improved the use of β-blockers in outpatients with stable congestive heart failure.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p22 

    This article focuses on a study regarding the evaluation of strategies to increase β-blocker use in heart failure, published in the 2003 issue of the journal "Circulation." For this study 169 patients who met the criteria for congestive heart failure, and had left ventricular ejection...

  • A nurse-facilator intervention improved the use of β-blockers in outpatients with stable congestive heart failure: COMMENTARY. Pugh, Jacqueline; Lawrence, Valerie // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p22 

    This article focuses on a study regarding the evaluation of strategies to increase β-blocker use in heart failure, published in the 2003 issue of the journal "Circulation." In the authors' opinion, the study shows that dedicating personnel to supervise specific treatment regimens is more...

  • Beta blockers' worth dependent on antidepressant use.  // Reactions Weekly;1/9/2010 Part 1 of 2, Issue 1283, p7 

    This article discusses research being done on the use of β-blockers in outpatients with heart failure. It references a study by R. L. Fosbøl et al., published in the November 2009 issue of the journal "Circulation: Heart Failure." The researchers used patient data from a number of...

  • Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or ... Waagstein, F.; Str�mblad, O.; Andersson, B.; B�hm, M.; Darius, M.; Delius, W.; Goss, F.; Osterziel, K.J.; Sigmund, M.; Trenkwalder, S.-P.; Wahlqvist, I. // European Journal of Heart Failure;Oct2003, Vol. 5 Issue 5, p679 

    Background: the effects of long-term administration of �-blockers on left ventricular (LV) function during exercise in patients with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM) are controversial. Patients and methods: patients with stable congestive heart...

  • Glau-opt.  // Royal Society of Medicine: Medicines;2002, p268 

    The article provides information on the drug Glau-opt. It is a proprietary, prescription-only preparation of the beta-blocker timolol maleate. It can be used for glaucoma treatment, and is available as eye-drops.

  • TICKER TROUBLE. Hitchens, Kathy // Drug Topics;5/8/2006, Vol. 150 Issue 9, p24 

    The article focuses on the standard core measures for the treatment of acute myocardial infarction, the leading cause of death in the U.S. Studies suggests that individuals at high risk of cardiovascular events benefit from tighter control of lipid levels. The Joint Commission on Accreditation...

  • AVEDOL -- GENERYCZNA POSTAĆ KARWEDILOLU, β-BLOKERA III GENERACJI O UDOWODNIONEJ SKUTECZNOÅšCI W TERAPII CHORÓB UKŁADU SERCOWO-NACZYNIOWEGO. POLIWCZAK, ADAM RAFAŁ; CHOJNOWSKA-JEZIERSKA, JULITA; BAŁA, AGNIESZKA; KOZIRÓG, MARZENA // Problemy Terapii Monitorowanej;jun2008, Vol. 19 Issue 2, p165 

    Beta-adrenolytics are drugs of established position in cardiovascular disorders treatment. Since development of this drug class in the late 50-ties of XX century, they are administered in the therapy of hypertension, coronary artery disease, arrhythmia, myocardial infarct and since several years...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics